JP2013507935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507935A5 JP2013507935A5 JP2012534414A JP2012534414A JP2013507935A5 JP 2013507935 A5 JP2013507935 A5 JP 2013507935A5 JP 2012534414 A JP2012534414 A JP 2012534414A JP 2012534414 A JP2012534414 A JP 2012534414A JP 2013507935 A5 JP2013507935 A5 JP 2013507935A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- essential
- seq
- mva virus
- orf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 21
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108700026244 Open Reading Frames Proteins 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108091029795 Intergenic region Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101710091045 Envelope protein Proteins 0.000 claims 1
- 108700039887 Essential Genes Proteins 0.000 claims 1
- 101710188315 Protein X Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25232609P | 2009-10-16 | 2009-10-16 | |
| US61/252,326 | 2009-10-16 | ||
| PCT/US2010/052929 WO2011047324A1 (en) | 2009-10-16 | 2010-10-15 | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507935A JP2013507935A (ja) | 2013-03-07 |
| JP2013507935A5 true JP2013507935A5 (https=) | 2013-10-31 |
| JP5789263B2 JP5789263B2 (ja) | 2015-10-07 |
Family
ID=43297031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534414A Active JP5789263B2 (ja) | 2009-10-16 | 2010-10-15 | 再構築された挿入部位を含有する組換え改変ワクシニアアンカラ（ｍｖａ）ワクシニアウイルス |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9133480B2 (https=) |
| EP (1) | EP2488649B1 (https=) |
| JP (1) | JP5789263B2 (https=) |
| AU (1) | AU2010306559B2 (https=) |
| CA (1) | CA2777744C (https=) |
| DK (1) | DK2488649T3 (https=) |
| WO (1) | WO2011047324A1 (https=) |
| ZA (1) | ZA201203551B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2062023T4 (en) * | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| DK2488649T3 (da) | 2009-10-16 | 2019-06-17 | Us Health | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| WO2016049492A1 (en) | 2014-09-26 | 2016-03-31 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Virus-based expression vectors and uses thereof |
| US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| EP3355924A1 (en) | 2015-09-29 | 2018-08-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Methods of treating and preventing amyotrophic lateral sclerosis |
| WO2017120577A1 (en) * | 2016-01-08 | 2017-07-13 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| WO2017136419A1 (en) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
| WO2017210181A1 (en) * | 2016-05-30 | 2017-12-07 | Geovax Inc. | Compositions and methods for generating an immune response to hepatitis b virus |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| WO2019152746A2 (en) | 2018-01-30 | 2019-08-08 | Emory University | Compositions and methods for promoting immune responses to human immunodeficiency virus |
| EP3790578A4 (en) | 2018-05-11 | 2022-04-06 | City of Hope | Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof |
| TWI810456B (zh) | 2019-05-22 | 2023-08-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| JP7456584B2 (ja) * | 2019-10-02 | 2024-03-27 | バイオノックス インコーポレイテッド | 腫瘍標的化タンパク質又はその断片、それに結合する抗体及びその使用 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| JP2024505274A (ja) | 2021-02-02 | 2024-02-05 | ゲオバックス インコーポレイテッド | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE315660T1 (de) | 2002-05-16 | 2006-02-15 | Bavarian Nordic As | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
| EP2363143A3 (en) | 2003-03-28 | 2012-02-15 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
| DK2062023T4 (en) * | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| EP2199400A1 (en) | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| DK2488649T3 (da) | 2009-10-16 | 2019-06-17 | Us Health | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
-
2010
- 2010-10-15 DK DK10771611.0T patent/DK2488649T3/da active
- 2010-10-15 AU AU2010306559A patent/AU2010306559B2/en active Active
- 2010-10-15 EP EP10771611.0A patent/EP2488649B1/en active Active
- 2010-10-15 CA CA2777744A patent/CA2777744C/en active Active
- 2010-10-15 JP JP2012534414A patent/JP5789263B2/ja active Active
- 2010-10-15 WO PCT/US2010/052929 patent/WO2011047324A1/en not_active Ceased
- 2010-10-15 US US13/502,205 patent/US9133480B2/en active Active
-
2012
- 2012-05-15 ZA ZA2012/03551A patent/ZA201203551B/en unknown
-
2015
- 2015-08-27 US US14/837,382 patent/US9879231B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507935A5 (https=) | ||
| Yang et al. | Pervasive initiation and 3′-end formation of poxvirus postreplicative RNAs | |
| JP2011004755A5 (https=) | ||
| JP2010259446A5 (https=) | ||
| HRP20180146T1 (hr) | Vektori i sljedovi namijenjeni liječenju bolesti | |
| JP2014516536A5 (https=) | ||
| JP2012509678A5 (https=) | ||
| RU2018122636A (ru) | Стабильные клеточные линии для продуцирования ретровирусов | |
| CN105861558A (zh) | 一种痘苗病毒穿梭载体及其制备方法和应用 | |
| Flick et al. | Functional analysis of the noncoding regions of the Uukuniemi virus (Bunyaviridae) RNA segments | |
| JP2013538554A5 (https=) | ||
| JP2012531205A5 (https=) | ||
| CN118234850A (zh) | 利用微rna来下调经修饰的安卡拉痘苗病毒(mva)的细胞毒性转基因的表达 | |
| CN103923943B (zh) | 一种基于腺病毒AdC7的表达载体及其构建方法 | |
| CN104195154B (zh) | 新城疫病毒Mukteswar中等毒力疫苗株反向遗传操作系统及其应用 | |
| CA2909225C (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| CN105274142A (zh) | 复制型重组人55型腺病毒载体及其制备方法和应用 | |
| RU2011137404A (ru) | Варианты гемагглютинина и нейраминидазы гриппа | |
| CN113736799B (zh) | 山羊副流感病毒3型感染性cDNA克隆构建方法及其应用 | |
| RU2014129220A (ru) | Новый аттенуированный полиовирус: pv-1 mono-cre-x | |
| US20080267992A1 (en) | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine | |
| CN101402945A (zh) | 表达抗传染性法氏囊病病毒微小rna重组禽腺联病毒的制备方法 | |
| CN104789598B (zh) | 一种表达红色荧光蛋白的重组家蚕质型多角体病毒的构建方法 | |
| CN117511888A (zh) | 一种基于CRISPR-Cas9技术的表达鸡传染性贫血病病毒T1P6毒株VP2蛋白的重组血清4型禽腺病毒及其制备方法 | |
| KR101677231B1 (ko) | 무혈청배지（serum free medium）를 이용한 메갈로사이티바이러스의 효율적 제조방법 |